|
1
|
Chang S, Dai M, Ren JS, Chen YH and Guo
LW: Estimates and prediction on incidence, mortality and prevalence
of lung cancer in China in 2008. Zhonghua Liu Xing Bing Xue Za Zhi.
33:391–394. 2010.(In Chinese).
|
|
2
|
Chien CR and Chen TH: A Bayesian model for
age, period, and cohort effects on mortality trends for lung
cancer, in association with gender-specific incidence and
case-fatality rates. J Thorac Oncol. 4:167–171. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Subramanian J, Madadi AR, Dandona M,
Williams K, Morgensztern D and Govindan R: Review of ongoing
clinical trials in non-small cell lung cancer: a status report for
2009 from the ClinicalTrials.govurisimpleClinicalTrials.gov website.
J Thorac Oncol. 5:1116–1119. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Collins FS: Cystic fibrosis: molecular
biology and therapeutic implications. Science. 256:774–779. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Riordan JR, Rommens JM, Kerem B, et al:
Identification of the cystic fibrosis gene: cloning and
characterization of complementary DNA. Science. 245:1066–1073.
1989. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
McWilliams RR, Rabe KG, Olswold C, De
Andrade M and Petersen GM: Risk of malignancy in first-degree
relatives of patients with pancreatic carcinoma. Cancer.
104:388–394. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
McWilliams RR, Petersen GM, Rabe KG, et
al: Cystic fibrosis transmembrane conductance regulator (CFTR) gene
mutations and risk for pancreatic adenocarcinoma. Cancer.
116:203–209. 2010.
|
|
8
|
Neglia JP, FitzSimmons SC, Maisonneuve P,
et al: The risk of cancer among patients with cystic fibrosis.
Cystic Fibrosis and Cancer Study Group. N Engl J Med. 332:494–499.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li Y, Sun Z, Wu Y, et al: Cystic fibrosis
transmembrane conductance regulator gene mutation and lung cancer
risk. Lung Cancer. 70:14–21. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Maisonneuve P, Marshall BC, Knapp EA and
Lowenfels AB: Cancer risk in cystic fibrosis: a 20-year nationwide
study from the United States. J Natl Cancer Inst. 105:122–129.
2013. View Article : Google Scholar
|
|
11
|
Mishra DK, Chen Z, Wu Y, Sarkissyan M,
Koeffler HP and Vadgama JV: Global methylation pattern of genes in
androgen-sensitive and androgen-independent prostate cancer cells.
Mol Cancer Ther. 9:33–45. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Son JW, Kim YJ, Cho HM, et al: Promoter
hypermethylation of the CFTR gene and clinical/pathological
features associated with non-small cell lung cancer. Respirology.
16:1203–1209. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ding S, Gong BD, Yu J, et al: Methylation
profile of the promoter CpG islands of 14 ‘drug-resistance’ genes
in hepatocellular carcinoma. World J Gastroenterol. 10:3433–3440.
2004.PubMed/NCBI
|
|
14
|
Abraham EH, Vos P, Kahn J, et al: Cystic
fibrosis hetero- and homozygosity is associated with inhibition of
breast cancer growth. Nat Med. 2:593–596. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
O’Connell MP, Fiori JL, Baugher KM, et al:
Wnt5A activates the calpain-mediated cleavage of filamin A. J
Invest Dermatol. 129:1782–1789. 2009. View Article : Google Scholar
|
|
16
|
Govindan R, Ding L, Griffith M, et al:
Genomic landscape of non-small cell lung cancer in smokers and
never-smokers. Cell. 150:1121–1134. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Brambilla E, Travis WD, Colby TV, Corrin B
and Shimosato Y: The new World Health Organization classification
of lung tumours. Eur Respir J. 18:1059–1068. 2001. View Article : Google Scholar
|
|
18
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: the 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li J, Ye L, Mansel RE and Jiang WG:
Potential prognostic value of repulsive guidance molecules in
breast cancer. Anticancer Res. 31:1703–1711. 2011.PubMed/NCBI
|
|
20
|
Smith SM, Vaughan JM, Donaldson CJ, et al:
Cocaine- and amphetamine-regulated transcript is localized in
pituitary lactotropes and is regulated during lactation.
Endocrinology. 147:1213–1223. 2006. View Article : Google Scholar
|
|
21
|
Vij N, Mazur S and Zeitlin PL: CFTR is a
negative regulator of NFkappaB mediated innate immune response.
PLoS One. 4:e46642009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
DiMango E, Ratner AJ, Bryan R, Tabibi S
and Prince A: Activation of NF-kappaB by adherent Pseudomonas
aeruginosa in normal and cystic fibrosis respiratory epithelial
cells. J Clin Invest. 101:2598–2605. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Boncoeur E, Roque T, Bonvin E, et al:
Cystic fibrosis trans-membrane conductance regulator controls lung
proteasomal degradation and nuclear factor-kappaB activity in
conditions of oxidative stress. Am J Pathol. 172:1184–1194. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Smith HW and Marshall CJ: Regulation of
cell signalling by uPAR. Nat Rev Mol Cell Biol. 11:23–36. 2010.
View Article : Google Scholar
|
|
25
|
Lipson D, Capelletti M, Yelensky R, et al:
Identification of new ALK and RET gene fusions from colorectal and
lung cancer biopsies. Nat Med. 18:382–384. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kohno T, Ichikawa H, Totoki Y, et al:
KIF5B-RET fusions in lung adenocarcinoma. Nat Med. 18:375–377.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Soda M, Choi YL, Enomoto M, et al:
Identification of the transforming EML4-ALK fusion gene in
non-small-cell lung cancer. Nature. 448:561–566. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Takeuchi K, Soda M, Togashi Y, et al: RET,
ROS1 and ALK fusions in lung cancer. Nat Med. 18:378–381. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Strongin AY: Proteolytic and
non-proteolytic roles of membrane type-1 matrix metalloproteinase
in malignancy. Biochim Biophys Acta. 1803:133–141. 2010. View Article : Google Scholar :
|
|
30
|
Lawrence T: The nuclear factor NF-kappaB
pathway in inflammation. Cold Spring Harb Perspect Biol.
1:a0016512009. View Article : Google Scholar
|
|
31
|
Sen R and Smale ST: Selectivity of the
NF-{kappa}B response. Cold Spring Harb Perspect Biol.
2:a0002572010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Pruliere-Escabasse V, Fanen P, Dazy AC, et
al: TGF-beta 1 downregulates CFTR expression and function in nasal
polyps of non-CF patients. Am J Physiol Lung Cell Mol Physiol.
288:L77–L83. 2005. View Article : Google Scholar
|
|
33
|
Howe KL, Wang A, Hunter MM, Stanton BA and
McKay DM: TGFbeta down-regulation of the CFTR: a means to limit
epithelial chloride secretion. Exp Cell Res. 298:473–484. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xie C, Jiang XH, Zhang JT, et al: CFTR
suppresses tumor progression through miR-193b targeting urokinase
plasminogen activator (uPA) in prostate cancer. Oncogene.
32:2282–2291. 2013. View Article : Google Scholar
|
|
35
|
Sun TT, Wang Y, Cheng H, et al: Disrupted
interaction between CFTR and AF-6/afadin aggravates malignant
phenotypes of colon cancer. Biochim Biophys Acta. 1843:618–628.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang JT, Jiang XH, Xie C, et al:
Downregulation of CFTR promotes epithelial-to-mesenchymal
transition and is associated with poor prognosis of breast cancer.
Biochim Biophys Acta. 1833:2961–2969. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ramsey BW, Davies J, McElvaney NG, et al:
A CFTR potentiator in patients with cystic fibrosis and the G551D
mutation. N Engl J Med. 365:1663–1672. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yang S, Yu BO, Sui Y, et al: CFTR chloride
channel is a molecular target of the natural cancer preventive
agent resveratrol. Pharmazie. 68:772–776. 2013.PubMed/NCBI
|
